Share on StockTwits
 

Equities researchers at UBS AG raised their price objective on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $2.50 to $7.50 in a research report issued on Monday, Analyst RN reports. The firm currently has a “neutral” rating on the stock. UBS AG’s price objective would indicate a potential upside of 4.90% from the company’s current price.

Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 6.29% during mid-day trading on Monday, hitting $6.70. 14,626,533 shares of the company’s stock traded hands. Ariad Pharmaceuticals has a 52 week low of $2.15 and a 52 week high of $23.00. The stock has a 50-day moving average of $4.86 and a 200-day moving average of $12.63. The company’s market cap is $1.244 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) last released its earnings data on Wednesday, November 6th. The company reported ($0.36) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.43) by $0.07. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $16.67 million. During the same quarter in the previous year, the company posted ($0.32) earnings per share. The company’s revenue for the quarter was up 1864.7% on a year-over-year basis. Analysts expect that Ariad Pharmaceuticals will post $-1.55 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on ARIA. Analysts at Citigroup Inc. downgraded shares of Ariad Pharmaceuticals from a “neutral” rating to a “sell” rating in a research note to investors on Monday. They now have a $5.50 price target on the stock, up previously from $2.50. Separately, analysts at Thomson Reuters/Verus downgraded shares of Ariad Pharmaceuticals from a “hold” rating to a “sell” rating in a research note to investors on Tuesday, December 24th. Finally, analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Ariad Pharmaceuticals in a research note to investors on Monday, December 23rd. They now have a $3.00 price target on the stock, up previously from $2.00. Five research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $6.86.

ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.